US2017065684A9PendingUtilityA9

Phenotypic reversion of pancreatic carcinoma cells

Assignee: PINCUS MATTHEWPriority: May 28, 2004Filed: Jul 27, 2015Published: Mar 9, 2017
Est. expiryMay 28, 2024(expired)· nominal 20-yr term from priority
A61K 38/00C12N 2710/10043A61K 38/46A61P 35/00C07K 2319/10C12Y 306/05002C07K 14/82C12N 15/86A61K 48/00C12N 2710/10032
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides peptides (including analogs and derivatives thereof) corresponding to residues 96-110 and 35-47 of ras-p21, which peptides have attached thereto a membrane-penetrating leader sequence. The subject peptides, analogs and derivatives thereof are useful in treatment of cancers and have been shown to induce phenotypic reversion of pancreatic cancer cells to non-cancerous cells. Pharmaceutical compositions comprising one or more subject peptides are also provided by the present invention. The present invention further provides replication incompetent Adenovirus (AdV) vectors comprising a promoter sequence and a nucleotide sequence encoding a subject peptide. Methods of treating cancer by administering one or more subject peptides, pharmaceutical compositions, and/or AdV vectors are also provided.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A replication incompetent Adenovirus (AdV) vector comprising a promoter sequence operably linked to a nucleotide sequence encoding a peptide, wherein the peptide comprises at least about ten contiguous amino acids of the amino acid sequence: TIEDSYRKQVVID (SEQ ID NO: 2), or an analog or derivative thereof. 
     
     
         2 . A method of treating a patient suffering from cancer that expresses oncogenic ras-p21 protein, said method comprising administering to the patient, a therapeutically effective amount of an AdV vector, said AdV vector comprising a promoter sequence operably linked to a nucleotide sequence encoding an isolated peptide, wherein the isolated peptide comprises the amino acid sequence TIEDSYRKQVVID (SEQ ID NO: 2) 
     
     
         3 . A method of inducing phenotypic reversion of cancerous cells to non-cancerous cells in a subject, wherein said cancerous cells express oncogenic ras-p21 protein, said method comprising administering to the subject, a therapeutically effective amount of an AdV vector, said AdV vector comprising a promoter sequence operably linked to a nucleotide sequence encoding an isolated peptide, wherein the isolated peptide comprises the amino acid sequence TIEDSYRKQVVID (SEQ ID NO: 2). 
     
     
         4 . The method of  claim 3  wherein the cancerous cells that express oncogenic ras-p21 protein are colon cancer cells, pancreatic cancer cells, non-small cell carcinoma of the lung, gastric cancer cells, bladder cancer cells or mesothelioma cells.

Join the waitlist — get patent alerts

Track US2017065684A9 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.